Fumoleau Pierre
Centre René Gauducheau, Medical Oncology Department, Nantes, France.
Semin Oncol. 2003 Apr;30(2 Suppl 3):15-8. doi: 10.1053/sonc.2003.37270.
The combination of gemcitabine and docetaxel exhibits good activity in the treatment of advanced breast cancer. Phase II trial response rates using 21- or 28-day schedules have ranged from 36% to 79% in patient populations with varying degrees of pretreatment. In studies of extensively pretreated anthracycline-resistant patients, response rates have ranged from 36% to 54%, with median times to disease progression of 7 to 8 months and median survival of 12.7 to 14 months. In less treatment-experienced patients, the combination produced an overall response rate of 79%, median time to progression of 7.6 months, and median survival of 24.5 months. Toxicity has primarily consisted of neutropenia. The combination warrants additional investigation as front-line chemotherapy and in patients with anthracycline-resistant and taxane-resistant advanced disease.
吉西他滨与多西他赛联合使用在晚期乳腺癌治疗中显示出良好活性。在不同预处理程度的患者群体中，采用21天或28天给药方案的II期试验缓解率在36%至79%之间。在对蒽环类耐药且接受过广泛预处理的患者进行的研究中，缓解率在36%至54%之间，疾病进展的中位时间为7至8个月，中位生存期为12.7至14个月。在治疗经验较少的患者中，该联合方案的总缓解率为79%，中位进展时间为7.6个月，中位生存期为24.5个月。毒性主要表现为中性粒细胞减少。该联合方案作为一线化疗以及用于蒽环类耐药和紫杉类耐药的晚期疾病患者值得进一步研究。
